Antiphospholipid Syndrome Clinical Research Task Force Report

Abstract

The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of six Task Forces developed by the 13^th International Congress on Antiphospholipid Antibodies (aPL) organization committee with the purpose of: a) evaluating the limitations of APS clinical research and developing guidelines for researchers to help improve the quality of APS research; and b) prioritizing the ideas for a well-designed multicenter clinical trial and discussing the pragmatics of getting such a trial done. Following a systematic working algorithm, the Task Force identified five major issues that impede APS clinical research and the ability to develop evidence-based recommendations for the management of aPL-positive patients: (1) aPL detection has been based on partially or non-standardized tests, and clinical (and basic) APS research studies have included patients with heterogeneous aPL profiles with different clinical event risks; (2) clinical (and basic) APS research studies have included a heterogeneous group of patients with different aPL-related manifestations (some controversial); (3) thrombosis and/or pregnancy risk stratification and quantification are rarely incorporated in APS clinical research; (4) most APS clinical studies include patients with single positive aPL results and/or low-titer aPL ELISA results; furthermore, study designs are mostly retrospective and not population based, with limited number of prospective and/or controlled population studies; and (5) lack of the understanding the particular mechanisms of aPL-mediated clinical events limits the optimal clinical study design. The Task Force recommended that there is an urgent need for a truly international collaborative approach to design and conduct well-designed prospective large-scale multi-center clinical trials of patients with persistent and clinically significant aPL profiles. An international collaborative meeting to formulate a good research question using ‘FINER’ (Feasible; Interesting; Novel; Ethical; and Relevant) criteria took place in November 2010.

Keywords

anticardiolipin antibodies antiphospholipid syndrome lupus anticoagulant

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Levy

de Meis

Pierangeli

. An adapted ELISA method for differentiating pathogenic from non-pathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay. Thromb Res 2004; 114: 575–577.

Pengo

Tripodi

Reber

. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737–1740.

Pengo

Ruffatti

Legnani

. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–242.

Hudson

Herr

Rauch

. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003; 30: 2385–2391.

Hansen

Kong

Moore

. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 2001; 28: 2018–2024.

Erkan

Yazici

Peterson

. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924–929.

Rosendaal

. Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost 1997; 78: 1–6.

Roubey

. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010; 19: 440–445.

10.

Hulley

. Designing clinical research, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.

11.

Pengo

Biasiolo

Gresele

. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5: 925–930.

12.

Lambrianides

Carroll

Pierangeli

. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184: 6622–6628.